New hope for anti-obesity drugs

Could the FDA’s supplemental approval of Novo Nordisk’s semaglutide for weight loss be a turning point for anti-obesity drugs? Could the FDA’s supplemental approval of Novo Nordisk’s semaglutide for weight loss be a turning point for anti-obesity drugs?